Welcome to our dedicated page for Lifestance Health Group SEC filings (Ticker: LFST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeStance Health Group filings document the company's outpatient mental healthcare business, Nasdaq-listed common stock and public-company governance. Its 8-K reports furnish quarterly and annual results, Regulation FD presentations, operating metrics, cash flow commentary and capital allocation disclosures.
The filing record also covers proxy matters, director elections, executive compensation, officer and board changes, equity incentive awards, share repurchase authorization, and common stock offering documents under shelf registration statements. These disclosures describe governance structure, securities registration, material agreements, stockholder selling activity, repurchases, and the risks and reporting obligations associated with LifeStance's virtual and in-person outpatient care model.
LifeStance Health Group, Inc. director filed a Form 4 reporting several sales of common stock through affiliated entities in December 2025. On 12/12/2025, Vitthal LLC and Shama LLC each sold 39,815 shares of LifeStance common stock at a weighted average price of $7.01 per share, with individual trades ranging from $7.00 to $7.045.
On 12/15/2025, Vitthal LLC sold 6,186 shares and Shama LLC sold 6,185 shares at a weighted average price of $7.00, with trades between $7.00 and $7.01. Following these transactions, the reporting person is shown as beneficially owning 1,382,175 shares indirectly through Vitthal LLC, 1,498,975 shares indirectly through Shama LLC, 57,619 shares directly, and 36,363 shares indirectly through Alpine Glow Capital, while disclaiming beneficial ownership beyond their pecuniary interests.
LifeStance Health Group, Inc. (LFST) disclosed that an executive sold company stock. On 11/21/2025, the Executive Vice President, Practice Operations reported selling 57,240 shares of LifeStance common stock at a weighted average price of $6.43 per share, in multiple trades between $6.41 and $6.50. After these sales, the executive beneficially owns 261,292 shares of LifeStance common stock. The filing notes that full trade details for each price within the range are available upon request.
LifeStance Health Group (LFST) reported an insider administrative transaction tied to RSU vesting. On November 10, 2025, an officer had 10,623 shares of common stock withheld at $6.43 per share to cover taxes from the net settlement of vested RSUs. The filing notes this was not an open‑market sale.
Following the transaction, the reporting person beneficially owned 318,532 shares directly. The individual is identified as Executive Vice President, Practice Operations.
LifeStance Health Group (LFST) reported a Form 4/A by its Chief People Officer correcting a prior filing. The amendment updates the number of shares withheld for taxes on PSUs vested on March 7, 2025 from 3,725 to 7,450, and updates holdings to 376,430 shares following the reported transactions.
Activity included: a grant of 76,142 RSUs on March 6, 2025; tax withholdings of 6,455 shares at $7.88 on March 6, 2025; PSU vestings of 27,740 and 32,052 on March 7, 2025; and additional tax withholdings of 7,450 shares at $7.59 and 8,606 shares at $7.59. The filing notes these withholdings reduce shares delivered and are not open‑market sales.
LifeStance Health Group (LFST) reported higher Q3 2025 results. Total revenue reached $363.8 million, up from $312.7 million a year ago. Income from operations was $7.4 million versus $0.05 million, and net income was $1.1 million compared with a prior-year net loss. For the first nine months, revenue was $1.04 billion and net loss narrowed to $2.0 million.
Cash and cash equivalents were $203.9 million, and net cash provided by operating activities rose to $88.6 million for the nine-month period. Long-term debt, net, was $269.4 million. Q3 Center Margin was $116.6 million and Adjusted EBITDA was $40.2 million. The company remained in compliance with debt covenants.
Commercial payors represented 90% of Q3 revenue, with government at 5% and self-pay at 4%. The interest rate swap matured on September 30, 2025. As of October 29, 2025, 389,000,281 common shares were outstanding.
LifeStance Health Group, Inc. (LFST) furnished quarterly materials. The company announced it furnished a press release covering results for the third quarter ended September 30, 2025 under Item 2.02, and a supplemental investor slide presentation under Item 7.01.
Both items are furnished, not filed, and are not incorporated by reference into other SEC filings unless expressly referenced. Exhibits include 99.1 (press release dated November 6, 2025) and 99.2 (supplemental slides), along with the Inline XBRL cover page file.
LifeStance Health Group (LFST) reported an insider equity award. A director acquired 74,766 shares of common stock on 08/20/2025 at $0.00, as shown on a Form 4.
The filing states these are restricted stock units (RSUs), with each RSU representing a right to receive one share of common stock. Following the reported transaction, the director beneficially owned 74,766 shares, held directly.
LifeStance Health Group (LFST) filed a Form 3 reporting the initial beneficial ownership of a director as of 08/20/2025. The filing states that no securities are beneficially owned. It was submitted by one reporting person and includes an Exhibit 24 Power of Attorney. This is an administrative disclosure required under Section 16 and does not reflect a transaction.
LifeStance Health Group insider report: Ann Varanakis, Chief People Officer and director, had restricted stock units vest on 08/26/2025. The issuer withheld 5,233 shares to satisfy tax withholding at $5.39 per share; this withholding is a net settlement and not an open-market sale. After the transaction, Ms. Varanakis beneficially owns 369,335 shares. The Form 4 was signed by an attorney-in-fact on 08/27/2025 and indicates the filing was made by one reporting person.
LifeStance Health Group reported a change in its board of directors. On August 19, 2025, William Miller resigned from the board and all its committees, effective immediately, and the company states his resignation was not due to any disagreement with the company. On August 20, 2025, the board appointed Sarah Personette as a new director.
In connection with her appointment, and under the company’s 2021 Equity Incentive Plan, Ms. Personette received an initial grant of 74,766 restricted stock units. These RSUs will vest based on time and performance conditions, subject to her continued service on the board.